Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics, Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOUTH SAN FRANCISCO, CALIF., SEPT. 02, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED THAT MEMBERS OF THE COMPANY MANAGEMENT TEAM WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES IN SEPTEMBER: CITI 2026 BIOPHARMA BACK TO SCHOOL CONFERENCE: FIRESIDE CHAT ON WEDNESDAY, SEPTEMBER 9, 2026 AT 3:00 PM EASTERN TIME IN NEW YORK, NY.

CYTOKINETICS TO PARTICIPATE IN SEPTEMBER INVESTOR CONFERENCES

ADDITIONAL RESULTS FROM ACACIA-HCM DEMONSTRATE IMPROVEMENTS IN CARDIAC STRUCTURE AND DIASTOLIC FUNCTION IN PATIENTS WITH NON-OBSTRUCTIVE HCM NEW ANALYSIS OF MAPLE-HCM FINDS AFICAMTEN OUTPERFORMED METOPROLOL ACROSS PRE-TRIAL TREATMENT GROUPS IN PATIENTS WITH OBSTRUCTIVE HCM SOUTH SAN FRANCISCO, CALIF., AUG. 29, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED THAT ADDITIONAL RESULTS FROM ACACIA-HCM (ASSESSMENT COMPARING A FICAMTEN TO PLACEBO ON CARDIAC ENDPOINTS IN ADULTS WITH NON-OBSTRUCTIVE HCM) AND MAPLE-HCM ( M ETOPROLOL VS A FICAMTEN IN PATIENTS WITH LVOT OBSTRUCTION ON EXERCISE CAPACITY IN HCM) WERE PRESENTED IN A LATE BREAKING CLINICAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2026 IN MUNICH, GERMANY AND SIMULTANEOUSLY PUBLISHED IN CIRCULATION AND THE JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY: HEART FAILURE, RESPECTIVELY.

CYTOKINETICS ANNOUNCES ADDITIONAL RESULTS FROM ACACIA-HCM AND MAPLE-HCM PRESENTED IN LATE BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2026

ACACIA-HCM IS THE FIRST PHASE 3 CLINICAL TRIAL TO SUCCESSFULLY DEMONSTRATE STATISTICALLY SIGNIFICANT IMPROVEMENTS ACROSS BOTH PATIENT-REPORTED AND PHYSICIAN-ASSESSED ENDPOINTS IN NON-OBSTRUCTIVE HCM SUPPLEMENTAL NEW DRUG APPLICATION TO BE SUBMITTED TO FDA IN FOURTH QUARTER COMPANY TO HOST INVESTOR EVENT AND WEBCAST TODAY AT 2:00 PM CENTRAL EUROPEAN SUMMER TIME (8:00 AM EASTERN TIME) SOUTH SAN FRANCISCO, CALIF., AUG. 28, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED THE PRIMARY RESULTS FROM ACACIA-HCM (ASSESSMENT COMPARING A FICAMTEN TO PLACEBO ON CARDIAC ENDPOINTS IN ADULTS WITH NON-OBSTRUCTIVE HCM), THE PIVOTAL PHASE 3 CLINICAL TRIAL OF AFICAMTEN IN PATIENTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (NHCM) WERE PRESENTED IN A HOT LINE SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2026 IN MUNICH, GERMANY, AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE .1 ACACIA-HCM MET BOTH DUAL PRIMARY ENDPOINTS, DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENTS FROM BASELINE TO WEEK 36 COMPARED TO PLACEBO IN BOTH KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE CLINICAL SUMMARY SCORE (KCCQ-CSS) AND MAXIMAL EXERCISE PERFORMANCE (PVO2).

CYTOKINETICS ANNOUNCES POSITIVE RESULTS FROM ACACIA-HCM PRESENTED IN HOT LINE SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2026 AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

HOT LINE PRESENTATION OF PRIMARY RESULTS FROM ACACIA-HCM TO ELABORATE ON POSITIVE TOPLINE RESULTS IN PATIENTS WITH NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

CYTOKINETICS ANNOUNCES UPCOMING PRESENTATIONS AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2026

SOUTH SAN FRANCISCO, CALIF., AUG. 18, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED THAT ON AUGUST 14, 2026 IT GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 27,565 SHARES OF COMMON STOCK AND 18,273 RESTRICTED STOCK UNITS (RSUS) THAT WILL BE SETTLED IN SHARES OF COMMON STOCK UPON VESTINGTO 12 EMPLOYEES, WHOSE EMPLOYMENT COMMENCED IN JULY AND AUGUST 2026 AS A MATERIAL INDUCEMENT TO THEIR EMPLOYMENT.

CYTOKINETICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

AUTHORISATION FROM MRHA AND RECOMMENDATION FROM NICE THIS ANNOUNCEMENT IS INTENDED FOR BUSINESS AND FINANCIAL MEDIA AND INVESTORS ONLY SOUTH SAN FRANCISCO, CALIF., JULY 30, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED THAT THE MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) HAS GRANTED MYQORZO (AFICAMTEN) A MARKETING AUTHORISATION ACROSS THE UNITED KINGDOM FOR THE TREATMENT OF SYMPTOMATIC (NEW YORK HEART ASSOCIATION, NYHA CLASS II-III) OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) IN ELIGIBLE ADULT PATIENTS.

CYTOKINETICS ANNOUNCES MHRA MARKETING AUTHORISATION FOR MYQORZO (AFICAMTEN) AND POSITIVE GUIDANCE FROM NICE FOR SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN ENGLAND AND WALES

SOUTH SAN FRANCISCO, CALIF., JULY 17, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED THAT ON JULY 15, 2026 IT GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 21,220 SHARES OF COMMON STOCK AND 14,067 RESTRICTED STOCK UNITS (RSUS) THAT WILL BE SETTLED IN SHARES OF COMMON STOCK UPON VESTINGTO 10 EMPLOYEES, WHOSE EMPLOYMENT COMMENCED IN JUNE AND JULY 2026 AS A MATERIAL INDUCEMENT TO THEIR EMPLOYMENT.

CYTOKINETICS ANNOUNCES THREE LATE-BREAKING SCIENCE ABSTRACTS AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2026

SOUTH SAN FRANCISCO, CALIF., JUNE 17, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED THAT ON JUNE 15, 2026 IT GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 24,784 SHARES OF COMMON STOCK AND 16,429 RESTRICTED STOCK UNITS (RSUS) THAT WILL BE SETTLED IN SHARES OF COMMON STOCK UPON VESTING AND 2,242 PERFORMANCE STOCK UNITS (PSUS) THAT, IF EARNED, WILL BE SETTLED IN SHARES OF COMMON STOCK UPON VESTING TO 12 EMPLOYEES, WHOSE EMPLOYMENT COMMENCED IN MAY AND JUNE, 2026, AS A MATERIAL INDUCEMENT TO THEIR EMPLOYMENT.

PROGRAM TO PROVIDE DONATIONS TO NON-PROFIT ORGANIZATIONS ALIGNED WITH CORPORATE VALUES DEADLINE FOR APPLICATIONS IS AUGUST 3, 2026 SOUTH SAN FRANCISCO, CALIF., JUNE 08, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED A CALL FOR PROPOSALS FOR ITS ANNUAL CYTOKINETICS CORPORATE GIVING PROGRAM.

Cytokinetics, Incorporated

CYTK

Price

Financial Reports

No items found.

Press Releases

Cytokinetics, Incorporated

CYTK.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CYTK